Tweakers maakt gebruik van cookies, onder andere om de website te analyseren, het gebruiksgemak te vergroten en advertenties te tonen. Door gebruik te maken van deze website, of door op 'Ga verder' te klikken, geef je toestemming voor het gebruik van cookies. Wil je meer informatie over cookies en hoe ze worden gebruikt, bekijk dan ons cookiebeleid.
MICREOS · Standplaats: Bilthoven · 28 september 2020
September 29, 2020
Gladskin Product Developer (Bilthoven)
Help us HAMAPASAP!
Your role at Micreos
In order to Help As Many As Possible As Soon As Possible (HAMAPASAP) we are expanding our Gladskin team in Bilthoven with a Gladskin Product Developer.
As a Gladskin Product Developer, you contribute to the successful setup, development, qualification and validation of endolysin-based Medical Devices and Cosmetic products. You participate in the execution and reporting of Formulation and Process development; Stability, Compatibility and Activity studies, and troubleshooting studies. For this purpose, you draft study plans and reports and ensure these are correctly documented according to current procedures. You contribute to the development of Micreos Human Health as the centre of excellence for endolysin-based topical products.
As Gladskin Product Developer your responsibility will be to :
Micreos offers a varied full time role (40 hours), with a possibility of a part time (min. 32 hours), within a young and enthusiastic team. The salary offered is in line with market conditions and you will be given the opportunity to make the fullest use of your talents. We offer you an ambitious and pleasant international working environment.
Is this the role you are looking for?
Our Micreos HR team is looking forward to receiving your CV and cover letter via .
Would you like to have more information on this super exciting role? Please send your questions to the above mentioned email address and we are more than happy to answer them!
Please only apply if you are eligible to work in the Netherlands.
Bacteria are all around us. Most of them are good and protect us, but some can cause irritation or infection. Antibiotics do not distinguish between good and bad bacteria and their use can lead to side effects and resistance. As they have been broadly used - often inappropriately - the emergence of antibiotic-resistant 'superbugs' is now a global concern. On the other hand, it has become evident that our microbiome, comprising billions of beneficial bacteria, is necessary for our health and should be left intact.
Micreos develops the world's first targeted antibacterial products, set to replace antibiotics. The company is viewed as the global leader spearheading this exciting new field. With Micreos endolysin technology, for the first time we can kill only the unwanted bacteria - including antibiotic resistant strains - while leaving the beneficial bacteria intact. In addition, research shows that the use of endolysins does not induce resistance. This unlocks a completely new approach in dealing with the bacteria around us - also enabling daily use, as long as needed while preserving the important biodiversity on our skin and in our gut. Based on its technology platform, Micreos has launched several products for inflammatory skin conditions such as acne, eczema and rosacea (brandname: Gladskin) and several food safety products marketed under the Phageguard brand. Micreos is also developing pharmaceutical products. See also www.micreos.com and www.gladskin.com
Acquisitions following this vacancy are not appreciated.
© 2010 - MICREOS